In an unexpected development, Gilead Sciences (GILD) disclosed that a generic version of its Truvada pill for preventing HIV will be sold by Teva Pharmaceuticals (TEVA) starting in September 2020, roughly a year earlier than had been expected.
Nonetheless, the news did little to assuage AIDS activists, who have been clamoring for a lower-cost version of the drug for the past few years, underscoring ongoing controversy over the cost of prescription medicines. Activists have complained that the price Gilead charges for its medicine has been a barrier to wider use and consequently thwarted efforts to eradicate the virus.
About the Author Reprints
